Indications and uses
Handwash to help reduce bacteria that potentially can cause disease. Recommended for repeated use.
Handwash to help reduce bacteria that potentially can cause disease. Recommended for repeated use.
Wet hands and forearms Apply appropriate amount (palmful) to hands and forearms Scrub hands and forearms thoroughly for 60 seconds Use scrub and/or nail brush to aid in cleaning. Rinse well Wipe dry with towel, repeat if necessary.
Drug Facts
Triclosan (0.35%)
Antiseptic Hand Cleanser
Discontinue use if irritation and redness develop. If condition persists more than 72 hours, consult a doctor.
In case of eye contact flush with water for 15 minutes. If irritation persists, get medical attention
Water, Sodium Laureth Sulfate, Sodium Lauryl Sulfate, Propylene Glycol, Lauramide DEA, Cocamide DEA, Cocamidopropyl betaine, Sodium Cumene Sulfonate, Citric Acid, Fragrance, DMDM Hydantoin, Sodium Chloride, FD&C Green #3.
| Bottle Label: |
HUSKY®
575
FOAMING ANTISEPTIC HAND CLEANER
A Powerful Antiseptic Cleanser for Handwashing
Enhanced with Moisturizers
KEEP OUT OF REACH OF CHILDREN
CAUTION
See Drug Facts panel for additional information.

| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 63779-575-05 | 2019-11-13 | C162847 | 48780-1 | 97449f38-beaf-f6ea-e053-dbdaa90aa703 | 4a7c04dc-7d51-4b98-aa1c-19f30c63d1f3 |
| 63779-575-20 | 2019-11-13 | C162847 | 48780-1 | 97449f38-beaf-f6ea-e053-dbdaa90aa703 | 4a7c04dc-7d51-4b98-aa1c-19f30c63d1f3 |
| 63779-575-42 | 2019-11-13 | C162847 | 48780-1 | 97449f38-beaf-f6ea-e053-dbdaa90aa703 | 4a7c04dc-7d51-4b98-aa1c-19f30c63d1f3 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63779-575-05 | HUSKY 575 Foaming Antiseptic Hand Cleaner | 3785 mL in 1 BOTTLE | LIQUID | 3785 | 2 | |
| 63779-575-20 | HUSKY 575 Foaming Antiseptic Hand Cleaner | 1100 mL in 1 BOTTLE | LIQUID | 1100 | 2 | |
| 63779-575-42 | HUSKY 575 Foaming Antiseptic Hand Cleaner | 50 mL in 1 BOTTLE | LIQUID | 50 | 2 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| triclosan | ACTIVE INGREDIENT | 4NM5039Y5X | 2 | |
| triclosan | ACTIVE MOIETY | 4NM5039Y5X | 2 | |
| citric acid monohydrate | INACTIVE INGREDIENT | 2968PHW8QP | 2 | |
| cocamidopropyl betaine | INACTIVE INGREDIENT | 5OCF3O11KX | 2 | |
| coco diethanolamide | INACTIVE INGREDIENT | 92005F972D | 2 | |
| dmdm hydantoin | INACTIVE INGREDIENT | BYR0546TOW | 2 | |
| FD&C Green NO. 3 | INACTIVE INGREDIENT | 3P3ONR6O1S | 2 | |
| lauric diethanolamide | INACTIVE INGREDIENT | I29I2VHG38 | 2 | |
| propylene glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| sodium chloride | INACTIVE INGREDIENT | 451W47IQ8X | 2 | |
| sodium laureth sulfate | INACTIVE INGREDIENT | BPV390UAP0 | 2 | |
| sodium lauryl sulfate | INACTIVE INGREDIENT | 368GB5141J | 2 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 63779-575 | 63779-575-05, 63779-575-42, 63779-575-20 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| triclosan | 4NM5039Y5X | ACTIB |
| water | 059QF0KO0R | IACT |
| sodium laureth sulfate | BPV390UAP0 | IACT |
| sodium lauryl sulfate | 368GB5141J | IACT |
| propylene glycol | 6DC9Q167V3 | IACT |
| lauric diethanolamide | I29I2VHG38 | IACT |
| cocamidopropyl betaine | 5OCF3O11KX | IACT |
| coco diethanolamide | 92005F972D | IACT |
| citric acid monohydrate | 2968PHW8QP | IACT |
| dmdm hydantoin | BYR0546TOW | IACT |
| sodium chloride | 451W47IQ8X | IACT |
| FD&C Green NO. 3 | 3P3ONR6O1S | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / SUBCUTANEOUS | 0.8 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRAVESICAL | 351 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / NASAL | 2.8 mg/1ml | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRAVENOUS | 0.9 %w/v | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TAMPON / VAGINAL | 62.1 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | TABLET, DELAYED RELEASE / ORAL | 97 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 2922 mg | ||
| FD&C Green NO. 3 | FD&C GREEN NO. 3 | 3P3ONR6O1S | ELIXIR / ORAL | NA | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | TABLET / ORAL | 231 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / TOPICAL | 4522 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | POWDER / RESPIRATORY (INHALATION) | NA | ||
| sodium laureth sulfate | SODIUM LAURETH-3 SULFATE | BPV390UAP0 | CREAM / TOPICAL | NA | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | ELIXIR / ORAL | 9306 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 3 mg | ||
| FD&C Green NO. 3 | FD&C GREEN NO. 3 | 3P3ONR6O1S | CAPSULE, EXTENDED RELEASE / ORAL | 0.16 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, COATED / ORAL | 16 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / RESPIRATORY (INHALATION) | 0.13 %w/w | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | FILM, EXTENDED RELEASE / TRANSDERMAL | 1.38 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SYSTEM / IONTOPHORESIS | 3.1 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, FILM COATED / ORAL | 240 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS | NA | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 608 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / SUBCUTANEOUS | 0.7 %w/v | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, ORALLY DISINTEGRATING / ORAL | 16 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAMUSCULAR | 17 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / TOPICAL | 5.28 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRACAVITARY | 0.82 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SHAMPOO / TOPICAL | 150 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | POWDER / TOPICAL | NA | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE / ORAL | 6 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / ORAL | 22602 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / SUBCUTANEOUS | 1.4 %w/v | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / RECTAL | 3315 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBMUCOSAL | 16 %w/v | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRA-ARTICULAR | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRATHECAL | 131 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAMUSCULAR | 0.86 %w/v | ||
| sodium laureth sulfate | SODIUM LAURETH-3 SULFATE | BPV390UAP0 | TABLET / ORAL | 0.91 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET / SUBLINGUAL | 24 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / ORAL | 148 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / EPIDURAL | 3535 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | GRANULE, FOR SUSPENSION / ORAL | 113 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRACAUDAL | 210 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | GRANULE, FOR SUSPENSION / ORAL | 162 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / IONTOPHORESIS | 0.02 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / SUBCUTANEOUS | 0.86 %w/v | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVITREAL | 10 %w/v | ||
| coco diethanolamide | COCO DIETHANOLAMIDE | 92005F972D | SUSPENSION / TOPICAL | 4 %w/w | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SOLUTION / OPHTHALMIC | 0.9 %w/w | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SUSPENSION / ORAL | 840 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SYSTEM / TOPICAL | 3.1 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / TOPICAL | 1 mg | ||
| lauric diethanolamide | LAURIC DIETHANOLAMIDE | I29I2VHG38 | SPONGE / TOPICAL | 5 %w/w | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 360 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 24 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / IRRIGATION | 1 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | CAPSULE, EXTENDED RELEASE / ORAL | 166 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET, COATED / ORAL | 123 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SPONGE / TOPICAL | 40 %w/w | ||
| coco diethanolamide | COCO DIETHANOLAMIDE | 92005F972D | SPONGE / TOPICAL | 2 %w/w |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| e2b15f71-1e47-44fd-8b05-e85222f3417a | 4a7c04dc-7d51-4b98-aa1c-19f30c63d1f3 | 2011-08-24 | Warnings | e2b15f71-1e47-44fd-8b05-e85222f3417a 4a7c04dc-7d51-4b98-aa1c-19f30c63d1f3 |
Adverse event summaries are temporarily unavailable. Other product information remains available.